Pavan Bhargava, MD

Extracellular Vesicles From Multiple Sclerosis White Matter Exhibit Synaptic, Mitochondrial, Complement and Ageing‐Related Pathway Dysregulation This study characterizes extracellular vesicles (EVs) separated from postmortem normal-appearing white matter of multiple sclerosis (MS) and control brains. Proteomic analysis revealed downregulation...

Our latest manuscript that identifies altered proteins in tissue derived extracellular vesilces from normal appearing white matter in MS. Journal of Extracellular Vesicles - Wiley Online Library isevjournals.onlinelibrary.wiley.com/doi/10.1002/...

For our #flowcytometry peeps, would you like to have a single fix/perm protocol that is optimised for everything? One that preserves fluorophores while allowing simultaneous TF and cytokine staining? How about 100-fold cheaper?

You got it:
currentprotocols.onlinelibrary.wiley.com/doi/10.1002/...

Our latest manuscript demonstrating the impact of diet on biological aging in people with MS. Fasting Mimicking Diets Reverse Accelerated Biological Aging in Multiple Sclerosis - Siavoshi - Annals of Neurology - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/...

New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, gui....

Very pleased to co-write this review with Bruce Cree and Steve Hauser on the future of #multiplesclerosis treatment

onlinelibrary.wiley.com/doi/10.1002/...

Our latest preprint showing alterations in the proteome of white matter EVs from MS patients compared to controls.

www.biorxiv.org/content/10.1...

Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis This randomized clinical trial investigates whether first-line disease-modifying therapy can be safely discontinued in patients with long-term stable multiple sclerosis.

Worth noting - in this population (median age around 54-55), discontinuation of first-line injectables, teriflunomide, and DMF after 5 years of stability led to substantially higher risk of disease activity. jamanetwork.com/journals/jam...